Predicting resectability of primary tumor and mesenteric lymph-node masses in patients with small-intestine neuroendocrine tumors.
Liver metastases
Liver resection
Primary tumor resection
Small intestine neuroendocrine tumors
Journal
Updates in surgery
ISSN: 2038-3312
Titre abrégé: Updates Surg
Pays: Italy
ID NLM: 101539818
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
04
11
2021
accepted:
27
01
2022
pubmed:
1
3
2022
medline:
21
9
2022
entrez:
28
2
2022
Statut:
ppublish
Résumé
Vascular infiltration may jeopardize resection of the primary tumor and mesenteric metastatic masses in small-intestine neuroendocrine tumors (SI-NETs). However, other factors may play a role in predicting resectability. After computed tomography (CT) scan, three radiological parameters were considered: (1) degree of superior mesenteric artery involvement (SMA) according to a previous classification (2) degree of superior mesenteric venous involvement (SMV) as either absent, peripheral or proximal (3) presence or not of mesenteric fibrosis retraction (MF). Pre-surgical parameters were matched to surgical outcome. Forty-nine consecutive patients were submitted to laparotomy. Of them, 37 had complete primary tumor and mesenteric masses resection. SMA (p = 0.001), SMV (p = 0.008), metastasis site (p = 0.001) and MF (p < 0.001) were all significantly associated with the likelihood to receive resection at univariate analysis. All the five patients with infiltration of SMV proximal to middle colic vein were unresectable. At multivariable analysis excluding SMA stage, the absence of MF (HR 13.1, I.C. 1.44-119; p = 0.002) was the only factor associated with the likelihood to receive primary tumor and mesentery radical surgery. SMA stage 3-up and/or signs of MF, as well as infiltration of SMV proximal to middle colic vein at CT scan are predictive of operative failure in patients with SI-NETs. The assessment of such factors should be always considered in the decision-making process of such patients especially in those with asymptomatic disease with synchronous unresectable liver metastases.
Sections du résumé
BACKGROUND
BACKGROUND
Vascular infiltration may jeopardize resection of the primary tumor and mesenteric metastatic masses in small-intestine neuroendocrine tumors (SI-NETs). However, other factors may play a role in predicting resectability.
METHODS
METHODS
After computed tomography (CT) scan, three radiological parameters were considered: (1) degree of superior mesenteric artery involvement (SMA) according to a previous classification (2) degree of superior mesenteric venous involvement (SMV) as either absent, peripheral or proximal (3) presence or not of mesenteric fibrosis retraction (MF). Pre-surgical parameters were matched to surgical outcome.
RESULTS
RESULTS
Forty-nine consecutive patients were submitted to laparotomy. Of them, 37 had complete primary tumor and mesenteric masses resection. SMA (p = 0.001), SMV (p = 0.008), metastasis site (p = 0.001) and MF (p < 0.001) were all significantly associated with the likelihood to receive resection at univariate analysis. All the five patients with infiltration of SMV proximal to middle colic vein were unresectable. At multivariable analysis excluding SMA stage, the absence of MF (HR 13.1, I.C. 1.44-119; p = 0.002) was the only factor associated with the likelihood to receive primary tumor and mesentery radical surgery.
CONCLUSIONS
CONCLUSIONS
SMA stage 3-up and/or signs of MF, as well as infiltration of SMV proximal to middle colic vein at CT scan are predictive of operative failure in patients with SI-NETs. The assessment of such factors should be always considered in the decision-making process of such patients especially in those with asymptomatic disease with synchronous unresectable liver metastases.
Identifiants
pubmed: 35224681
doi: 10.1007/s13304-022-01251-3
pii: 10.1007/s13304-022-01251-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1697-1704Informations de copyright
© 2022. Italian Society of Surgery (SIC).
Références
Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y et al (2017) Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 3(10):1335–1342
doi: 10.1001/jamaoncol.2017.0589
Keck KJ, Maxwell JE, Utria AF, Bellizzi AM, Dillon JS, O’Dorisio TM et al (2018) The distal predilection of small bowel neuroendocrine tumors. Ann Surg Oncol 25(11):3207–3213
doi: 10.1245/s10434-018-6676-2
Niederle B, Pape U-F, Costa F et al (2016) ENETS Consensus Guidelines ENETS Consensus Guidelines update for neuroendocrine neoplasms of the Jejunum and Ileum. Neuroendocrinology 103:125–138
doi: 10.1159/000443170
Walsh JC, Schaeffer DF, Kirsch R et al (2016) Ileal “carcinoid” tumors—small size belies deadly intent: high rate of nodal metastasis in tumors ≤1 cm in size. Hum Pathol 56:123–127
doi: 10.1016/j.humpath.2016.05.023
Åkerström G, Hellman P, Hessman O (2005) Midgut carcinoid tumours: surgical treatment and prognosis. Best Pract Res Clin Gastroenterol 19:717–728
doi: 10.1016/j.bpg.2005.05.005
Wu L, Chen F, Chen S, Wang L (2018) The Lymph node ratio optimizes staging in patients with small intestinal neuroendocrine tumors. Neuroendocrinology. https://doi.org/10.1159/000491017
doi: 10.1159/000491017
pubmed: 29920496
Chen L, Song Y, Zhang Y, Chen M, Chen J (2018) Exploration of the exact prognostic significance of lymphatic metastasis in jejunoileal neuroendocrine tumors. Ann Surg Oncol 25(7):2067–2074
doi: 10.1245/s10434-018-6511-9
Landry CS, Lin HY, Phan A et al (2013) Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors. World J Surg 37:1695–1700
doi: 10.1007/s00268-013-1918-8
Ohrvall U, Eriksson B, Juhlin C et al (2000) Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J Surg 4:1402–1408
doi: 10.1007/s002680010232
Lardière-Deguelte S, de Mestier L, Appéré F, Vullierme MP, Zappa M, Hoeffel C et al (2016) Toward a preoperative classification of lymph node metastases in patients with small intestinal neuroendocrine tumors in the era of intestinal-sparing surgery. Neuroendocrinology 103(5):552–559
doi: 10.1159/000441423
Bosman FT, Carneiro F, Hruban RH et al (2010) WHO classification of tumours of the digestive system, 4th edn. IARC, Lyon
Pape U-F, Perren A, Niederle B et al (2012) ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95:135–156
doi: 10.1159/000335629
Daskalakis K, Karakatsanis A, Hessman O, Stuart HC, Welin S, TiensuuJanson E et al (2018) Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival. JAMA Oncol 4(2):183–189
doi: 10.1001/jamaoncol.2017.3326
Lewis A, Raoof M, Ituarte PHG, Williams J, Melstrom L, Li D et al (2018) Resection of the primary gastrointestinal neuroendocrine tumor improves survival with or without liver treatment. Ann Surg. https://doi.org/10.1097/SLA.0000000000002809
doi: 10.1097/SLA.0000000000002809
pubmed: 28187045
Pantongrag-Brown L, Buetow PC, Carr NJ, Lichtenstein JE, Buck JL (1995) Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation. AJR Am J Roentgenol 164:387–391
doi: 10.2214/ajr.164.2.7839976
Hellman P, Lundström T, Ohrvall U, Eriksson B, Skogseid B, Oberg K et al (2002) Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 26(8):991–997
doi: 10.1007/s00268-002-6630-z
Rodríguez Laval V, Pavel M, Steffen IG, Baur AD, Dilz LM, Fischer C, Detjen K, Prasad V, Pascher A, Geisel D, Denecke T (2018) Mesenteric fibrosis in midgut neuroendocrine tumors: functionality and radiological features. Neuroendocrinology 106(2):139–147. https://doi.org/10.1159/000474941
doi: 10.1159/000474941
pubmed: 28384635
Blažević A, Zandee WT, Franssen GJH, Hofland J, van Velthuysen MF, Hofland LJ, Feelders RA, de Herder WW (2018) Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours. Endocr Relat Cancer 25(3):245–254
doi: 10.1530/ERC-17-0282
Laskaratos FM, Walker M, Wilkins D, Tuck A, Ramakrishnan S, Phillips E, Gertner J, Megapanou M, Papantoniou D, Shah R, Banks J, Vlachou E, Garcia-Hernandez J, Woodbridge L, Papadopoulou A, Grant L, Theocharidou E, Watkins J, Luong TV, Mandair D, Caplin M, Toumpanakis C (2018) Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours. Neuroendocrinology 107(3):292–304. https://doi.org/10.1159/000493317
doi: 10.1159/000493317
pubmed: 30153671
Kaçmaz E, Chen JW, Tanis PJ, Nieveen van Dijkum EJM, Engelsman AF (2021) Postoperative morbidity and mortality after surgical resection of small bowel neuroendocrine neoplasms: a systematic review and meta-analysis. J Neuroendocrinol 33(8):e13008. https://doi.org/10.1111/jne.13008
doi: 10.1111/jne.13008
pubmed: 34235792
pmcid: 8459236